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Abstract
In France, more than 2.5 million patients are currently treated with levothyroxine, mainly as the marketed product 
 Levothyrox®. In March 2017, at the request of French authorities, a new formulation of  Levothyrox® was licensed, with 
the objective of avoiding stability deficiencies of the old formulation. Before launching this new formulation, an average 
bioequivalence trial, based on European Union recommended guidelines, was performed. The implicit rationale was the 
assumption that the two products, being bioequivalent, would also be switchable, allowing substitution of the new for the 
old formulation, thus avoiding the need for individual calibration of the dosage regimen of thyroxine, using the thyroid-
stimulating hormone level as the endpoint, as required for a new patient on initiating treatment. Despite the fact that both 
formulations were shown to be bioequivalent, adverse drug reactions were reported in several thousands of patients after 
taking the new formulation. In this opinion paper, we report that more than 50% of healthy volunteers enrolled in a success-
ful regulatory average bioequivalence trial were actually outside the a priori bioequivalence range. Therefore, we question 
the ability of an average bioequivalence trial to guarantee the switchability within patients of the new and old levothyroxine 
formulations. We further propose an analysis of this problem using the conceptual framework of individual bioequivalence. 
This involves investigating the bioavailability of the two formulations within a subject, by comparing not only the popula-
tion means (as established by average bioequivalence) but also by assessing two variance terms, namely the within-subject 
variance and the variance estimating subject-by-formulation interaction. A higher within individual variability for the new 
formulation would lead to reconsideration of the appropriateness of the new formulation. Alternatively, a possible subject-
by-formulation interaction would allow a judgement on the ability, or not, of doctors to manage patients effectively during 
transition from the old to the new formulation.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-019-00747 -3) contains 
supplementary material, which is available to authorized users.
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1 Introduction
In France, more than 2.5 million patients are receiving treat-
ment with levothyroxine [1] and most are administered the 
product  Levothyrox®. In March 2017, Merck Serono, the 
French subsidiary of the German pharmaceutical company, 
Merck KGaA, launched a new formulation of  Levothyrox®. 
It is anticipated that this new formulation will soon be mar-
keted in 21 European Union (EU) countries [2]. Despite the 
fact that both formulations were shown to be bioequivalent, 
several thousand patients reported adverse drug reactions 
(ADRs), following this replacement [3]. In this opinion 
paper, we report that more than 50% of healthy volunteers, 
enrolled into a study which demonstrated average bioequiva-
lence (ABE), were actually outside the a priori bioequiva-
lence range. We therefore question the ability of an ABE 
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trial to guarantee the switchability, within a patient, of the 
new and old levothyroxine formulations.
The objectives in developing a new formulation of 
 Levothyrox® (hereafter named  Levothyrox®NF) were two 
fold; to improve pharmaceutical stability and to ensure a 
potency specification over a shelf-life of at least 18 months. 
The active drug (synthetic l-thyroxine, levothyroxine, or 
L-T4) was the same as in the original formulation (hereafter 
named  Levothyrox®OF). The excipients only were changed, 
with the replacement of lactose by mannitol and citric acid, 
both of which have been claimed by French authorities as 
excipients not known to have a recognised action on or to 
affect the administered dose of  Levothyrox®NF [4]. Fol-
lowing this substitution and over 13 months of marketing 
the new formulation (from 27 March, 2017 to 17 April, 
2018), as many as 31,411 patients had declared ADRs to 
the French network of pharmacovigilance centres, after 
switching from the old to the new  Levothyrox® formulation; 
this number is approximately 1.43% of patients treated with 
 Levothyrox®NF [3]. Most ADRs occurred shortly after this 
imposed change and the official pharmacovigilance review 
reported, for 1745 patients documented for their thyroidal 
status before and after the switch between the two formula-
tions, that 23% were hypothyroid, 10% were hyperthyroid, 
while 67% were normal for thyroid-stimulating hormone 
status [1].
The conclusion of the French regulatory agency is that 
it is not possible, from their data analysis, to suggest an 
hypothesis to account for these ADRs. The possibility of 
bio-inequivalence between the old and the new formulations 
has been excluded, following a large pharmacokinetic study 
comparing the formulations [5]. This conclusion was based 
on the 90% confidence interval for the area under the curve 
(AUC) plasma concentration, which is a measure of internal 
exposure within the pre-defined European regulatory limits 
of 90.00–111.11%, hereafter reported as 0.9–1.11 limits.
2  Precisely What is Indicated by an Average 
European Union or US Food and Drug 
Administration Bioequivalence Trial?
It is important to recognise that a bioequivalence (BE) trial, 
conducted in healthy volunteers according to both the EU 
2010 revised guidance [6] and the corresponding US Food 
and Drug Administration (FDA) guideline [7], does not 
guarantee that each individual patient in the target popula-
tion, who switches from an older reference (R) formulation 
to a new test (T) formulation, will be “similarly” exposed 
to levothyroxine, nor is it intended to do so. In the over-
view of comments received on the draft EU BE guideline 
[8], one can read the following comment from stakeholders 
“The draft guideline deals only with average bioequivalence. 
The Population and Individual bioequivalence approaches 
are not mentioned anywhere; therefore, it is not clear as to 
whether these approaches are acceptable”. The European 
Medicines Agency’s succinct but uninformative answer was, 
“The average bioequivalence approach is the recommended 
method to establish bioequivalence”. In commenting on the 
2010 revision of the EU guideline, Morais and Lobato [9] 
drew attention to the conceptual shift in European Medicines 
Agency guidance between the previous and the 2010 revised 
EU guideline on BE, with the replacement of a clinically ori-
entated guideline by a quality-control orientated guideline. 
This explains why the notion of “essential similarity”, which 
was the basis for comparability of two medicinal products, to 
support their interchangeability in clinical use, was deleted 
owing to a lack of a sound legal basis. Conversely, the adop-
tion of a ‘quality-like’ approach implies “less reliance on 
judgment based on clinical considerations” [9]. The new 
objective is to ensure that formulation differences can be 
detected because “pharmacokinetic parameters such as AUC 
and Cmax are more sensitive to difference in formulation 
and manufacturing process than to clinical endpoints” [9]. 
This new EU position is legally more supportable than the 
previous guidance, but it implicitly considers healthy sub-
jects involved in an ABE trial to be equivalent to homogene-
ous ‘walking’ chromatographic columns, rather than being 
representative of a future heterogeneous targeted patient 
population.
Key Points 
A new formulation of  Levothyrox® has been launched 
in France to replace an existing formulation, which is 
no longer marketed, and it is anticipated that this new 
formulation will be also marketed in the near future in all 
European Union countries, i.e. it will then be prescribed 
to several million further patients.
Shortly after this compulsory substitution, adverse 
drug reactions were reported to the French network of 
pharmacovigilance centres, involving several thousand 
patients.
It was shown that more than 50% of 204 healthy volun-
teers, enrolled into a successful European Union regula-
tory average bioequivalence trial, were actually outside 
the a priori bioequivalence range.
It is suggested that the appropriate conceptual framework 
to document switchability between the old and the new 
 Levothyrox® formulations is individual bioequivalence.
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3  Formulation Substitution is Subject 
to National Regulation and is Not Dealt 
with by European Union Guidelines
Formulation switchability to support a substitution of one 
product with another is a scientific principle not dealt with 
by EU guidelines (vide infra). Substitution policy is a 
national issue, not one regulated by the EU [6]. In contrast, 
in USA, the concept of individual bioequivalence (IBE), 
and its merits compared to ABE, have been extensively 
investigated [10–12]. It should be understood that the aim 
of ABE studies is solely to compare the population means 
between T and R products and thus to ensure that the mean 
(median) AUCs of the two formulations are sufficiently 
close to guarantee that their ratio is contained within the 
acceptable pre-defined regulatory limits. Average bioequiv-
alence is typically used in the pre-marketing approval of 
new generic formulations. However,  Levothyrox®NF is not 
a new generic formulation offered as a possible alternative 
to  Levothyrox®OF for a new patient. It is a new formula-
tion designed to replace  Levothyrox®OF and the number 
of patients for which this change was imposed in France 
between March and June 2017 is estimated to be 2,188,432 
[3]. Hence, the key question that should have been addressed 
before the marketing of  Levothyrox®NF is: can a patient 
already treated with  Levothyrox®OF be safely and effec-
tively switched from this no longer available formulation to 
the new formulation? A study demonstrating ABE does not 
answer this question, i.e. the demonstration of ABE between 
 Levothyrox®OF and  Levothyrox®NF does not ensure their 
switchability.
4  Appropriate Conceptual Framework 
to Document Switchability Between Two 
Formulations is Individual Bioequivalence
The concept underlying switchability is that each patient 
has his/her own individual therapeutic window, that is, a 
range of plasma concentrations providing appropriate effi-
cacy and safety. If a formulation change is made, the new 
formulation should ensure a drug exposure profile precisely 
located in this individual therapeutic window, thereby ensur-
ing unchanged safety and efficacy [12].
For thyroxine, the therapeutic window is narrow; it is 
classified as a narrow therapeutic index drug [13], dosage for 
which each patient should be carefully titrated. This is pro-
vided for, first, by the availability of multiple dosage product 
strengths and, second, by the reduction in the classical BE 
acceptance interval from 0.80–1.25 to 0.90–1.11.
The appropriate conceptual framework to document 
switchability is IBE; the explicit aim is to document the 
switchability between two formulations. The concept of IBE 
was introduced more than 25 years ago [14] to address the 
limitations of ABE trials in addressing the issue of switch-
ability. An IBE study compares the exposure obtained with 
each formulation within each individual subject, thereby 
ensuring that each individual will respond similarly to the 
two formulations. Investigation of IBE requires comparing 
the closeness of the distribution of bioavailability between 
T and R formulations by establishing not only population 
means (as for ABE) but also two variance terms, namely, the 
within-subject variance and the variance estimating the sub-
ject-by-formulation interaction (for further detail and critical 
comments see [11, 12, 15]). This interaction term documents 
the extent to which the individual differences between T and 
R formulations are similar across individual subjects. The 
FDA reported that an interaction is important when about 
10% or more of individuals’ R/T ratios are outside the pre-
defined a priori BE range [12]. Individual bioequivalence 
has been both extensively discussed and challenged and 
then, finally, not adopted by regulatory authorities. It is 
beyond the scope of this paper to discuss in detail the advan-
tages and limitations of IBE. However, simply concluding 
that the IBE concept is not clinically relevant because some 
authors or organisations consider that there is no evidence 
for failure of ABE for approved generics, such as [16], is not 
acceptable. Compared to ABE, IBE studies require more 
complicated and expensive designs and are associated with 
several regulatory issues. These include defining IBE, how 
to measure it and how to analyse data (for detailed reviews, 
see a series of 13 articles published in a special issue of 
Statistics in Medicine in 2000 expressing the advantages and 
disadvantages [17]).
We concur with the opinion of the FDA Individual Popu-
lation Bioequivalence Working Group [12] that the subject-
by-formulation interaction, the most critical variance term 
to explore for switchability, is highly relevant. In this com-
mentary, it is proposed that the BE of the two formulations 
of  Levothyrox®, and more especially the subject-by-formu-
lation interaction to assess whether IBE is established for the 
formulations, merits further consideration.
5  For  Levothyrox®, More Than 50% 
of Subjects Enrolled in a Large European 
Union Regulatory Average Bioequivalence 
Trial were Actually Outside the a Priori 
Bioequivalence Range
Because of public and media concerns, and the desire of 
the French regulatory authorities to ensure full transparency 
for this major public health crisis, the BE dossier, including 
its raw data, have been made public: it can be down-loaded 
on the Agence Nationale de Sécurité du Médicament et des 
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Produits de Santé [18]. The dossier provided data on L-T4, 
hereafter named T4. The T4 concentration–time profiles of 
204 healthy individuals, for both old and new formulations, 
were retrieved. Blood samples were taken before administra-
tion (baseline) and regularly up to 72 h post-administration. 
For individual subject concentration–time profiles, AUC was 
computed by trapezoidal methods. According to the 2010 
European Medicines Agency guideline, “If the substance 
being studied is endogenous, the calculation of pharmacoki-
netic parameters should be performed using baseline correc-
tion so that the calculated pharmacokinetic parameters refer 
to the additional concentrations provided by the treatment” 
[6]. In our analysis, both baseline-adjusted AUC, obtained 
by subtracting the baseline concentration from each post-
administration concentration, and unadjusted AUC were 
calculated, to take account of overall T4 exposure, when 
evaluating IBE. It is rational to recognise, from the patient 
perspective, that it is this overall exposure that is clinically 
relevant.
The experimental design was a 2 × 2 cross-over. As the 
sequence of administration of the formulations to each indi-
vidual was not reported in the public dossier, possible period 
or sequence effects were not considered in our analysis. 
However, for each individual subject, the exposure ratios 
AUCnew/AUCold (hereafter named IER) were comput-
able for adjusted and non-adjusted T4 concentrations. This 
is of interest when documenting IBE, because as indicated 
above, the proportion of subjects outside the a priori BE 
interval (here 0.90–1.11) is directly related to the variance 
term measuring the subject-by-formulation interaction. This 
variance can, under some conditions, be estimated from the 
standard deviation of the individual mean formulation dif-
ferences on a logarithmic scale (see [12] for explanation and 
[19] for demonstration). For example, assuming that the ratio 
of overall T/R means is 1 (as is the case for  Levothyrox®) and 
assuming a bivariate normal distribution for the between-
subject distribution, the proportion of individual T/R ratios 
outside the a priori BE interval of 0.80–1.25 is 13.7% for a 
standard deviation of 0.15 for the subject-by-formulation 
interaction, 0.15 being the cut-off value selected by the FDA 
[12]. The data and the R-script used to perform the compu-
tation and details of data analysis including management 
of missing data are available as Electronic Supplementary 
Material on the journal website.
Individuals were then classified into five groups, respec-
tively corresponding to an IER in one of the following inter-
vals: 0–0.8, 0.8–0.9, 0.9–1.11, 1.11–1.25, 1.25–∞ (Table 1). 
Figure 1 illustrates the distributions of IER computed for T4 
with and without adjustment for the baseline.
For the baseline-adjusted ratio (Fig.  1, left panel; 
Table 1), less than 50% of subjects (32.8%) were located in 
the a priori BE interval of 0.9–1.11, with an expected per-
centage having a 95% confidence interval of 26.4–39.7. The 
corresponding percentage for the unadjusted IER (Fig. 1, 
right panel; Table 1) was 83.3%, with a 95% confidence 
interval of 77.5–88.2.
In the dossier, the ABE was established on the adjusted 
AUC from zero to 72 h and, even if statistical re-analysis 
of the data set had not been possible, as a consequence of a 
lack of public information on trial design, it is acknowledged 
that the trial [5] and analyses were conducted professionally 
according to current EU guidelines. However, it is proposed 
that the IBE, focusing on intra-individual variability, as well 
as on a possible subject-by-formulation interaction, merits 
consideration.
The published experimental design [5] was not planned 
for statistical analysis of an IBE and this report does not 
claim with statistical protection that the two formulations 
are not switchable. Nevertheless, plotting the observed IER 
highlights a major “warning signal” requiring consideration 
for two reasons. First, less than 50% of subjects are within 
the a priori BE interval of 0.90–1.11 when (in compliance 
with the EU guideline) the baseline-adjusted AUC is consid-
ered. Second, there is an apparently more favourable finding, 
when the unadjusted AUC is considered. Whilst such data 
analysis is not recommended by the EU guidelines, it con-
stitutes an important consideration, when discussing the rel-
evance of IBE. Indeed, for the healthy subjects in this trial, 
having normal thyroid function, the administered T4 likely 
triggered a negative feedback on endogenous T4 secretion, 
Table 1  Number of individuals from 204 investigated subjects in 
each class of individual exposure ratio (IER)
AUC area under the curve
a For the baseline-adjusted T4 and the unadjusted T4, the number 
and the percentage of individuals from the 204 investigated subjects 
in each class of IER (AUCnew/AUCold) and the corresponding 95% 
confidence interval (Clopper–Pearson) are provided. It is of note that 
less than 50% of subjects were located in the a priori bioequivalence 
interval of 0.9–1.11, when the regulatory-adjusted AUC is consid-
ered, whereas the unadjusted AUC provided more homogeneous IER 
results with some 83% of patients located in the a priori bioequiva-
lence interval
Class intervals Unadjusted  T4a 
AUCnew/AUCold 
ratio
Baseline-adjusted  T4a 
AUCnew/AUCold ratio
< 0.8 2
1.0 (0.1–3.5)
40
19.6 (14.4–25.7)
0.8–0.9 17
8.3 (4.9–13.0)
32
15.7 (11.0–21.4)
0.9–1.11 (a priori 
regulatory inter-
val)
170
83.3 (77.5–88.2)
67
32.8 (26.4–39.7)
1.11–1.25 15
7.4 (4.2–11.8)
26
12.7 (8.5–18.1)
> 1.25 0
0.0 (0–1.8)
39
19.1 (14.0–25.2)
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with a buffering effect on T4 plasma concentration, thus 
resulting in a smaller IER dispersion than when adjusted 
AUC is considered. Axiomatically, it can be hypothesised 
that such rapid physiological adjustments will be less effi-
cient or even absent in the targeted clinical population, these 
patients having either reduced or a total lack of thyroid func-
tion. In this case, it is ADRs that triggered the required dos-
age adjustment to ensure an individual euthyroidal status. 
Therefore, the appropriateness of using healthy euthyroi-
dal subjects to assess BE for  Levothyrox® formulations is 
questionable.
6  As More Than 50% of Individuals 
were Outside the A Priori 
Bioequivalence Range, the Existence 
of a Subject‑by‑Formulation Interaction 
is Not Unlikely
The fact that more 50% of individuals were outside the a pri-
ori BE range suggests the existence of a subject-by-formu-
lation interaction, as reported for several drugs (for a recent 
review see [20]). Indeed, such findings have been reported 
previously for thyroxine. It was shown that the magnitude 
of the influence of pH on the pharmacokinetics of levothy-
roxine is formulation dependent and that two formulations 
that are considered as BE in healthy volunteers under fasting 
conditions may be not necessarily BE in patients with altered 
gastric pH [21] but that the absorption extent of a liquid 
formulation of T4 was not altered by proton-pump inhibi-
tors [22]. Likewise, liquid T4 formulations are more effi-
cacious than tablets in patients with malabsorption receiv-
ing T4 either for replacement or for suppressive therapy, 
whereas there were no significant differences in patients in 
the absence of malabsorption [23]. These literature reports 
indicate that there are clinical situations in which establish-
ing equivalence for thyroxine in healthy volunteers may not 
translate unequivocally to equivalence in all patients. They 
illustrate potential concerns for many patients treated with 
 Levothyrox®NF.
7  New, but not the Old,  Levothyrox® 
Formulation Contains Mannitol, 
an Excipient Considered to be Critical 
for Drugs such as Levothyroxine Having 
a Low Permeability
A subject-by-formulation interaction can arise when either 
a subgroup of subjects or individual subjects have differ-
ing pharmacokinetic profiles for either a T or R formulation 
from the remainder of the population enrolled in a BE trial 
[19]. Mechanistically, it is attributable to some character-
istic of this subpopulation leading to altered drug absorp-
tion. Levothyroxine is classified in the Biopharmaceutical 
Classification System as a Class III substance, i.e. one hav-
ing high solubility but low permeability [24]. The new, but 
not the old,  Levothyrox® formulation contains mannitol, an 
osmotic excipient considered to be critical [25], especially 
for Class III drugs (for a general review of the impact of 
osmotically active excipients on bioavailability and BE of 
Biopharmaceutical Classification System Class III drugs, see 
[26]). Indeed, low permeability compounds are often subject 
to site-dependent absorption, and their bioavailability can be 
dependent on gastrointestinal tract transit time, which may 
be influenced by mannitol. For example, the bioavailability 
of the  H2-receptor antagonist, cimetidine, in a chewable tab-
let containing 2.264 g of mannitol, was reduced by 29% and 
this was due to a reduction in small intestine transit time of 
20% [27]. The magnitude of effect of mannitol was shown 
to be dose dependent in the range of 0.755–2.265 g [28]. For 
the new formulation of  Levothyrox®, the amount of man-
nitol is approximately 70 mg for a 100-mg tablet [29] and 
a patient may take two tablets. Whether a small amount of 
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Fig. 1  Distribution of individual exposure ratio (IER) [area under the 
curve new/area under the curve old] obtained with baseline-adjusted 
T4 (left panel), and unadjusted T4 (right panel) plasma concentra-
tions. Blue vertical straight lines are the acceptable pre-defined limits, 
namely 0.9 and 1.11. An individual with an IER within these limits 
has an observed variation of exposure of less than 10% when switch-
ing from the old to the new formulation. Red dotted vertical straight 
lines, 0.8 and 1.25, are respectively, the limits below and above which 
the variation of exposure is greater than 20% when switching from 
the old to the new formulation
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mannitol, of some 140 mg, can affect small intestine transit 
time and thereby be associated with decreased bioavailabil-
ity of levothyroxine is not known. Moreover, according to 
Chen et al. [26] the quantitative dose–response relationship 
for mannitol on cimetidine/ranitidine absorption may not 
be extrapolated to other substances because, as well as an 
osmotic effect, an osmotically active excipient may influence 
either the absorption mechanism or the absorption site. For 
sorbitol, an isomer of mannitol, it has been reported that 
very small amounts (7, 50 or 60 mg) can affect drug absorp-
tion and this effect appears to be subject dependent [30].
8  Concluding Comments
In conclusion, a statistical analysis conducted in the con-
ceptual framework of IBE would have enabled: (1) docu-
mentation of possible higher intra-individual variability 
for the new compared with the old formulation and, hence, 
possible reconsideration of the development of this new for-
mulation; indeed, a fine individual subject calibration, due 
to day-to-day erratic variability in bioavailability, would be 
very difficult to establish, thus rendering less informative 
the ability of a snapshot sample to estimate the actual thy-
roid-stimulating hormone level; (2) consideration of a pos-
sible subject-by-formulation interaction, thus allowing both 
regulatory authorities and prescribing clinicians to be better 
placed to manage and systematically supervise all patients 
during transition from the old to the new formulation; and 
(3) thereby to anticipate a possible new titration for patients 
on whom the new formulation has been imposed. Average 
bioequivalence as the regulatory recommended BE approach 
notwithstanding, a requirement to explore a possible subject-
by-formulation interaction to ensure switchability between 
products is justified, especially when millions of patients 
are involved. Such was the case for  Concerta® (methylphe-
nidate) and associated generic products; a subject-by-formu-
lation analysis for each pharmacokinetic metric was recom-
mended by the FDA in addition to the establishment of ABE 
[31]. Such analysis is warranted on the grounds of optimal 
risk management both for the millions of existing patients 
and for future EU patients undergoing thyroid-deficiency 
treatment with a drug, for which replacement of an old with 
a new formulation has been known for many years to be 
problematic internationally [32].
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